CDKN2A and cancer: As shown in Figure 5C, ChIP-qPCR assays determined that PVT1 was required for the EZH2 recruitment to and silencing of p15 and p16. Moreover, overexpression of EZH2 has been described in cancers including bladder [20], gastric [21], lung [22], and hepatocellular carcinoma [24].